Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diannexin in Kidney Transplant Recipients
NCT00615966Phase 2Completed
- Sponsor
- Alavita Pharmaceuticals, Inc.
- Start
- Feb 2008
- Primary completion
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Diannexin in ischemia-reperfusion injury (IRI), sponsored by Alavita Pharmaceuticals, Inc.. Started Feb 2008; status: completed.
02
Drugs
Diannexin
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00615966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00615966.